Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.

By Rodney A. Hayward, P. Reaven, Wyndy Wiitala, G. Bahn, D. Reda, Ling Ge, M. Mccarren, W. Duckworth, N. Emanuele. New England Journal of Medicine, 2015

641 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/641f85945b7866e908ac4c67ba433351efbdf3cb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

Citations in the corpus

6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. (2021, background): “However, 10-year follow-up of the VADT cohort (61) did demonstrate a reduction in the risk of cardiovascular events (52.”
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “6 fewer cardiovascular events per 1,000 personyears), whereas mortality risk remained the same between treatment groups (78).”
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019 (2018, background): “of the VADT cohort (33) showed a reduction in the risk of cardiovascular events (52.”
6. Glycemic Targets: Standards of Medical Care in Diabetes—2020 (2019, background): “However, 10-year follow-up of theVADT cohort (40) showeda reduction in the risk of cardiovascular events (52.”
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. (2015, background): “The few favorable demonstrations of reduced rates of cardiovascular events with predominantly glucose-lowering therapies have required more protracted follow-up than routinely occurs in clinical trials.(4,7) Although our study had only approximately 2 years of follow-up, sufficient numbers of cardio”
6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. (2021, background): “10-year follow-up of the VADT cohort (52) showed a reduction in the risk of cardiovascularevents(52.”